文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

急诊科区域麻醉:关键药物治疗学考量综述

Regional anesthesia in the emergency department: A review of key pharmacotherapeutic considerations.
PubMed 文献 · Am J Emerg Med · 2026-04-03
一句话结论急诊区域麻醉需掌握局麻药结构活性关系、体重给药、超声引导与脂肪乳剂可及性,以在减少阿片类全身不良反应的同时防控局麻药全身毒性。

该综述指出,阿片类药物相关风险与阿片危机推动了急诊多模式镇痛的发展,区域麻醉在超声引导下使用日益增多。文章阐述了常用局麻药(酰胺类如利多卡因、布比卡因、罗哌卡因、左布比卡因;酯类如阿替卡因、氯普鲁卡因)的结构活性关系、起效时间、作用时长与毒性差异,以及肾上腺素、地塞米松、α2受体激动剂等佐剂对阻滞时长与镇痛的影响及安全与操作考量。识别局麻药全身毒性(LAST)是安全实践的核心,强调体重给药、超声引导、监测与即刻可及的脂肪乳剂治疗。订单集、药师参与和结构化培训等系统化方法支持急诊区域麻醉的一致安全实施。

要点

  • 常用局麻药分酰胺类(利多卡因、布比卡因、罗哌卡因、左布比卡因)与酯类(阿替卡因、氯普鲁卡因),起效、时长与毒性差异影响急诊选药。
  • 肾上腺素、地塞米松与α2受体激动剂等佐剂可能延长神经阻滞时长或改善镇痛,但引入安全与操作考量。
  • 识别局麻药全身毒性(LAST)是安全实践核心,强调体重给药、超声引导、监测与即刻可及的脂肪乳剂治疗。
  • 订单集、药师参与与结构化培训等系统化方法支持急诊区域麻醉的一致安全应用。
  • 安全整合区域麻醉需药物治疗学素养、标准化系统与多学科支持,以优化镇痛同时最小化风险。

适用人群与场景

  • 急诊科(ED)需多模式镇痛的患者,因阿片类药物相关风险与阿片危机而推动区域麻醉应用。

处置流程与药物剂量

  • 区域麻醉应在超声引导下实施,并强调体重给药、监测与即刻可及的脂肪乳剂治疗以防控LAST。
  • 常用局麻药包括酰胺类(如利多卡因、布比卡因、罗哌卡因、左布比卡因)与酯类(如阿替卡因、氯普鲁卡因),依据起效、时长与毒性差异选药。
  • 佐剂如肾上腺素、地塞米松与α2受体激动剂可能延长神经阻滞时长或改善镇痛,但需考虑安全与操作因素。
  • 系统化方法包括订单集、药师参与与结构化培训,以支持急诊区域麻醉的一致安全应用。

红旗征与不能漏的情况

  • 局麻药全身毒性(LAST)的识别是安全实践核心,需立即处理并确保脂肪乳剂治疗可及。

研究设计与关键结果

  • 综述指出急诊区域麻醉使用频率增加,局麻药与佐剂的药理特性决定其优势、局限与治疗地位。
  • 酰胺类与酯类局麻药在起效、作用时长与毒性特征上存在差异,影响急诊患者选药。
  • 安全实践核心包括体重给药、超声引导、监测与即刻可及的脂肪乳剂治疗以应对LAST。
  • 订单集、药师参与与结构化培训等系统化方法支持急诊区域麻醉的一致安全应用。

证据类型、等级与局限

  • 证据类型:综述。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 急诊区域麻醉应基于局麻药结构活性关系与药理学特性选择药物,并采用体重给药、超声引导与监测。
  • 实施区域麻醉时需确保脂肪乳剂治疗即刻可及,以应对LAST。
  • 使用肾上腺素、地塞米松或α2受体激动剂等佐剂时需权衡延长阻滞或改善镇痛的获益与安全及操作考量。
  • 可通过订单集、药师参与与结构化培训等系统化方法支持急诊区域麻醉的安全应用。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: Opioid-associated risks and the opioid epidemic have accelerated interest in multimodal analgesia in the emergency department (ED). Regional anesthesia offers a targeted approach with reduced risk of systemic adverse effects and is increasingly used under ultrasound guidance.

OBJECTIVE: This concise, evidence-based review explores pharmacological principles of local anesthetics describing key aspects of structure-activity relationship, providing context for agent selection. Additional considerations include dosing strategy, adjunctive medications, potential risks, toxicity mitigation, and operationalization of regional anesthesia in the ED.

DISCUSSION: Regional anesthesia is used with increased frequency in the ED. Pharmacologic properties of commonly used local anesthetics and adjunctive agents determine their advantages and limitations as well as place in therapy. There are a variety of anesthetic agents, including amides (e.g., lidocaine, bupivacaine, ropivacaine, levobupivacaine) and esters (e.g., articaine, chloroprocaine) with differences in onset, duration, and toxicity profiles that influence agent selection in ED patient populations. Adjuncts such as epinephrine, dexamethasone, and alpha-2 agonists may extend nerve block duration or improve analgesia but introduce safety and operational considerations. Recognition of local anesthetic systemic toxicity (LAST) remains central to safe practice, underscoring the importance of weight-based dosing, ultrasound guidance, monitoring, and immediate access to lipid emulsion therapy. Systems-based approaches such as order sets, pharmacist involvement, and structured training support consistent and safe application of regional anesthesia in the ED setting.

CONCLUSIONS: Safe integration of regional anesthesia in the ED requires pharmacologic literacy, standardized systems, and multidisciplinary support to optimize analgesia while minimizing risk.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Ray L, Gottlieb M, Long B, et al. Regional anesthesia in the emergency department: A review of key pharmacotherapeutic considerations. Am J Emerg Med. 2026. PMID: 42000675. doi:10.1016/j.ajem.2026.04.003

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。